Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2-locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection Aftimos, P., Neven, P., Pegram, M., van Oord, C., Dees, E., Schroder, C., Jager, A., Bulat, I., Chap, L., Maglakelidze, M., Hamilton, E., Cristofanilli, M., Ulahannan, S., Boers, J., Iqbal, R., Crijanovschi, A., Wolfgang, C. D., Tao, W., Sipes, C., Malik, R., Jain, S. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000618737700377